These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28852147)

  • 21. Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
    Sato M; Sato S; Shintani D; Hanaoka M; Ogasawara A; Miwa M; Yabuno A; Kurosaki A; Yoshida H; Fujiwara K; Hasegawa K
    BMC Cancer; 2022 Jan; 22(1):59. PubMed ID: 35027024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.
    Cooper TT; Dieters-Castator DZ; Liu J; Siegers GM; Pink D; Veliz L; Lewis JD; Lagugné-Labarthet F; Fu Y; Steed H; Lajoie GA; Postovit LM
    J Ovarian Res; 2024 Jul; 17(1):149. PubMed ID: 39020428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
    Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
    Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
    J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer.
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    BMC Cancer; 2018 Sep; 18(1):883. PubMed ID: 30200903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
    Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS; Lee JY; Kim HS; Nam EJ; Kim SW; Kim YT
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSP60 predicts survival in advanced serous ovarian cancer.
    Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
    Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry.
    Ali RH; Kalloger SE; Santos JL; Swenerton KD; Gilks CB
    Int J Gynecol Pathol; 2013 Nov; 32(6):529-35. PubMed ID: 24071867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma.
    Herzog M; Verdenik I; Kobal B; Černe K
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa.
    Communal L; Medrano M; Sircoulomb F; Paterson J; Köbel M; Rahimi K; Hoskins P; Tu D; Lheureux S; Oza A; Ailles L; Provencher D; Rottapel R; Mes-Masson AM
    Mod Pathol; 2020 Nov; 33(11):2361-2377. PubMed ID: 32514162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
    Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
    Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
    Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
    Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.